title: Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
abstract: The aim of the study was to investigate whether interleukin-10 (IL-10) genetic polymorphisms influence this cytokine production as well as the incidence and outcome of diffuse large B-cell lymphoma (DLBCL). The frequency of IL-10(-1082G) allele was found to be higher in 199 patients with DLBCL as compared with 112 control subjects (0.47 versus 0.39, P =.043). Increased serum levels of IL-10 were associated with adverse prognostic factors and poor DLBCL outcome. The frequencies of IL-10(-819T) and IL-10(-592A) alleles were lower in patients with elevated IL-10 serum levels (0.155 versus 0.32, P =.14). As compared with patients carrying the IL-10(-1082AA) genotype, patients with the IL-10(-1082G) allele (IL-10(-1082GG/GA) genotypes) had higher complete remission rate (78% [confidence interval (CI), 71%-85%] versus 65% [CI, 52%-78%], P =.07), 5-year freedom from progression (FFP) (60% [CI, 52%-68%] versus 40% [CI, 27%-53%], P =.013), and overall survival (OS) (63% [CI, 55%-71%] versus 33% [CI, 20%-45%], P =.0009). Among factors of the International Prognostic Index, IL-10(-1082G) allele remained an independent variable, predicting longer freedom from progression (FFP) (RR [relative risk] =.76, P =.00035) and OS (RR =.78, P =.0015). These results indicate that IL-10 production contributes to the clinical course of DLBCL and that this phenomenon involves a substantial genetic component.
authors.affiliation: Equipe d'Accueil 3737 Pathologie des Cellules Lymphoïdes, Université Claude Bernard, Lyon, France.
authors.forename: Ewa
authors.initials: E
authors.lastname: Lech-Maranda
authors.forename: Lucile
authors.initials: L
authors.lastname: Baseggio
authors.forename: Jacques
authors.initials: J
authors.lastname: Bienvenu
authors.forename: Carole
authors.initials: C
authors.lastname: Charlot
authors.forename: Françoise
authors.initials: F
authors.lastname: Berger
authors.forename: Dominique
authors.initials: D
authors.lastname: Rigal
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
mesh_terms: D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D016753:Interleukin-10 / Q000097:blood / Q000235:genetics*; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000235:genetics / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016753:Interleukin-10